---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-250305"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2023-10-04T23:59:59+00:00"
generated_at: "2026-06-10T05:05:58.785582+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Teva and Sanofi partner on anti-TL1A therapy TEV-574 for IBD; $500M upfront

## Summary
- Teva receives €469M ($500M) upfront and up to €940M ($1B) in development/launch milestones.
- Companies share development costs equally and split net profits/losses in major markets.
- Sanofi leads Phase 3 program; Teva commercializes in Europe/Israel, Sanofi in North America/Asia.
- TEV-574 is in Phase 2b for ulcerative colitis and Crohn's disease; initial data expected in 2024.

## SEC filing metadata
- accession: 0001193125-23-250305
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2023-10-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000119312523250305/0001193125-23-250305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000119312523250305/d547410d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-250305
- JSON: https://secwatch.observer/filing/0001193125-23-250305.json
- Plain text: https://secwatch.observer/filing/0001193125-23-250305.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.